Daily Broadcaster

“Pancreatic Cancer Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Cancer Pipeline Landscape.

The Pancreatic Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pancreatic Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Pancreatic Cancer treatment therapies with a considerable amount of success over the years.

• Pancreatic Cancer companies working in the treatment market are AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics CMG 901 Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others, are developing therapies for the Pancreatic Cancer treatment

• Emerging Pancreatic Cancer therapies in the different phases of clinical trials are- LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others are expected to have a significant impact on the Pancreatic Cancer market in the coming years.

• In October 2026, Reports from the European Society for Medical Oncology (ESMO) Congress presented updated Phase I findings for Incyte’s investigational KRAS G12D inhibitor, INCB161734, in combination with modified FOLFIRINOX chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Among 54 patients with KRAS G12D-mutated tumors, the combination demonstrated a confirmed objective response rate of 89%. These preliminary results highlight the potential of KRAS-targeted therapies in pancreatic cancer, although further studies are required to validate their efficacy and safety in larger patient populations.

• In October 2026, Incyte continued to advance INCB161734 through its Phase III DAWN-303 clinical program for pancreatic ductal adenocarcinoma (PDAC). This development highlights the increasing focus on targeting KRAS G12D mutations, which are commonly associated with pancreatic cancer. However, INCB161734 remains an investigational therapy and has not received FDA approval for pancreatic cancer.

• In August 2026, The US Food and Drug Administration (FDA) approved Revolution Medicines’ Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have undergone at least one previous systemic treatment or are ineligible for multiagent systemic therapy. As a RAS-targeted inhibitor, the therapy marks a significant development in the treatment landscape for advanced pancreatic cancer.

• In July 2026, Targeting the RAS signaling pathway continued to be a key area of focus in pancreatic cancer drug development. Notable investigational programs to monitor in July include daraxonrasib and KRAS G12D inhibitors such as INCB161734. However, the sources reviewed did not confirm a specific pancreatic cancer-related FDA approval or a new pivotal clinical trial result announced in July 2026.

• In May 2026, The US FDA issued a “safe to proceed” letter authorizing Revolution Medicines to launch an expanded access protocol for daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma. This decision allows eligible patients to potentially access the investigational therapy before it receives FDA approval, provided they meet the expanded access program’s eligibility criteria and requirements.

• In August 2026, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for adults with advanced pancreatic cancer who have previously received at least one systemic treatment and whose tumors harbor a KRAS G12C mutation, confirmed through an FDA-approved diagnostic test. Olomorasib is an investigational, highly selective, next-generation KRAS G12C inhibitor. The designation adds to olomorasib’s earlier Breakthrough Therapy designation in combination with KEYTRUDA (pembrolizumab) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying a KRAS G12C mutation and PD-L1 expression of at least 50%, as identified by FDA-approved testing.

• In July 2026, At the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), new Phase III data for daraxonrasib generated significant excitement among oncologists and researchers, marking a potentially important development in the treatment of advanced pancreatic cancer. The RASolute 302 trial evaluated daraxonrasib in patients with advanced pancreatic cancer who had previously received chemotherapy, comparing the investigational therapy with standard chemotherapy. Results showed that median survival approximately doubled among patients treated with daraxonrasib, offering renewed hope in a disease where treatment advances have been limited for decades. The encouraging findings sparked strong reactions at the meeting, with clinicians highlighting the potential of daraxonrasib to provide a meaningful new treatment option for patients with advanced pancreatic cancer.

• In May 2026, An investigational therapy that could provide new hope for patients with pancreatic cancer has received expanded access authorization from the U.S. Food & Drug Administration (FDA), enabling a broader group of patients to access the drug while clinical studies continue. Pancreatic cancer remains among the most aggressive and difficult-to-treat cancers. The therapy, daraxonrasib (formerly known as RMC-6236), is designed to target mutations in the RAS gene family. Among these, KRAS mutations are the most prevalent, driving more than 90% of pancreatic cancer cases. For decades, researchers considered KRAS mutations largely “undruggable” due to the challenges in effectively targeting them with existing treatments, though recent scientific advances have begun to change that outlook.

• In May 2026, The U.S. Food and Drug Administration (FDA) has authorized Revolution Medicines to move forward with an expanded access program (EAP) for its investigational RAS(ON) inhibitor, daraxonrasib (RMC-6236), in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The program is intended to provide eligible patients who are unable to enroll in clinical trials with access to the therapy. In a separate announcement, Revolution Medicines reported that its Phase III RASolute 302 study evaluating daraxonrasib successfully achieved its primary endpoints. According to the company, patients with previously treated metastatic pancreatic cancer who received daraxonrasib demonstrated a median overall survival of 13.2 months, compared with 6.7 months in patients treated with chemotherapy.

• In March 2026, Revolution Medicines announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline including daraxonrasib will be featured at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

• In February 2026, Novocure announced that the U.S. Food and Drug Administration (FDA) approved OPTUNE Pax for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.

• In January 2026, ChipScreen Biosciences received regulatory approval from China’s National Medical Products Administration (NMPA) to initiate a new clinical trial for chiauranib in pancreatic cancer, marking a key advancement following encouraging earlier data.

• In January 2026, Novita Pharmaceuticals, Inc., a privately held clinical-stage biopharmaceutical company focused on developing innovative oncology therapies using its proprietary fascin inhibitor platform, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational small-molecule fascin inhibitor NP-G2-044 for the treatment of pancreatic cancer. Pancreatic cancer remains one of the most lethal cancers, with an estimated five-year survival rate of around 12% and very limited effective treatment options, especially for patients with advanced disease.

• In November 2025, Artios Pharma is advancing a pipeline of oncology therapies, with alnodesertib as its lead candidate, currently under investigation for second-line pancreatic cancer and third-line colorectal cancer. The company announced that it has raised $115 million in a Series D funding round, which will be used to further develop its oncology pipeline. A significant portion of the funds is earmarked for alnodesertib, supporting its ongoing clinical trials in pancreatic and colorectal cancer.

• In November 2025, Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical firm with an extensive portfolio of drug candidates addressing hard-to-treat cancers and viral infections, announced that it has established a research and material transfer agreement with the University of North Carolina at Chapel Hill (UNC). This collaboration will support investigator-initiated preclinical studies assessing Annamycin for the treatment of pancreatic cancer.

Pancreatic Cancer Overview

Pancreatic cancer is a condition where malignant cells develop in the pancreatic tissues. This type of cancer originates within the pancreas, an abdominal organ positioned behind the lower portion of the stomach. The pancreas, resembling a slender pear lying horizontally, measures approximately 6 inches in length and serves as a gland in the body.

Get a Free Sample PDF Report to know more about Pancreatic Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight

Emerging Pancreatic Cancer Drugs Under Different Phases of Clinical Development Include:

• LYNPARZA (olaparib): AstraZeneca

• KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

• Elraglusib (9 ING 41): Actuate Therapeutics

• DF 7001: Dragonfly Therapeutics CMG 901 Keymed B

• TNG260: Tango Therapeutics

• ATA 3271: Atara Biotherapeutics

• CMG 901: Keymed Biosciences Co.Ltd

• CT-0508: Carisma Therapeutics Inc

• CUE-102: Cue Biopharma

• BOLD-100: Bold Therapeutics

• CM24: Purple Biotech Ltd

• ENB-003: ENB Therapeutics

• GRT-C903: Gritstone bio

• AZD0171: AstraZeneca

• CAN-2409: Candel Therapeutics

• Mitazalimab: Alligator Bioscience

• Pamrevlumab: FibroGen

• NIS793: Novartis AG

• Masitinib: AB Science

• Glufosfamide: Eleison Pharmaceutical

Pancreatic Cancer Route of Administration

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Pancreatic Cancer Molecule Type

Pancreatic Cancer Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Pancreatic Cancer Pipeline Therapeutics Assessment

• Pancreatic Cancer Assessment by Product Type

• Pancreatic Cancer By Stage and Product Type

• Pancreatic Cancer Assessment by Route of Administration

• Pancreatic Cancer By Stage and Route of Administration

• Pancreatic Cancer Assessment by Molecule Type

• Pancreatic Cancer by Stage and Molecule Type

DelveInsight’s Pancreatic Cancer Report covers around 200+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Pancreatic Cancer product details are provided in the report. Download the Pancreatic Cancer pipeline report to learn more about the emerging Pancreatic Cancer therapies

Some of the key companies in the Pancreatic Cancer Therapeutics Market include:

Key companies developing therapies for Pancreatic Cancer are – AB Science, AstraZeneca, Eleison Pharmaceuticals, ImmunityBio, SynerGene Therapeutics, Inc., Mirati Therapeutics Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, Incyte Corporation, AbbVie, Ability Pharmaceuticals SL, Legend Biotech USA Inc, Biomea Fusion Inc., Astellas Pharma Inc, Cue Biopharma, PureTech, and others.

Pancreatic Cancer Pipeline Analysis:

The Pancreatic Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer Treatment.

• Pancreatic Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pancreatic Cancer drugs and therapies

Pancreatic Cancer Pipeline Market Drivers

• Emergence of genomic profiling technologies and selective molecular targeted therapies, emergence of effective therapeutic options for metastatic pool are some of the important factors that are fueling the Pancreatic Cancer Market.

Pancreatic Cancer Pipeline Market Barriers

• However, delayed detection and screening of the disease, stromal barriers to drug delivery within the TME in pancreatic cancer and other factors are creating obstacles in the Pancreatic Cancer Market growth.

Scope of Pancreatic Cancer Pipeline Drug Insight

• Coverage: Global

• Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics CMG 901 Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others

• Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others

• Pancreatic Cancer Therapeutic Assessment: Pancreatic Cancer current marketed and Pancreatic Cancer emerging therapies

• Pancreatic Cancer Market Dynamics: Pancreatic Cancer market drivers and Pancreatic Cancer market barriers

Request for Sample PDF Report for Pancreatic Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Pancreatic Cancer Report Introduction

2. Pancreatic Cancer Executive Summary

3. Pancreatic Cancer Overview

4. Pancreatic Cancer- Analytical Perspective In-depth Commercial Assessment

5. Pancreatic Cancer Pipeline Therapeutics

6. Pancreatic Cancer Late Stage Products (Phase II/III)

7. Pancreatic Cancer Mid Stage Products (Phase II)

8. Pancreatic Cancer Early Stage Products (Phase I)

9. Pancreatic Cancer Preclinical Stage Products

10. Pancreatic Cancer Therapeutics Assessment

11. Pancreatic Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pancreatic Cancer Key Companies

14. Pancreatic Cancer Key Products

15. Pancreatic Cancer Unmet Needs

16 . Pancreatic Cancer Market Drivers and Barriers

17. Pancreatic Cancer Future Perspectives and Conclusion

18. Pancreatic Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services